Skip to main content

Advertisement

Table 1 Baseline demographic and clinical characteristics of 39 evaluated patients with gemcitabine-refractory advanced pancreatic cancer

From: Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study

Characteristic No. of patients %
Age
 ≤ 60 years 25 64.1
 > 60 years 14 35.9
Sex
 Male 29 74.4
 Female 10 25.6
ECOG PS
 0 2 5.1
 1 35 89.7
 2 2 5.1
Extent of disease
 Locally advanced 7 17.9
 Metastatic 32 82.1
Primary tumor location
 Head 18 46.1
 Body 9 23.1
 Tail 12 30.8
Metastatic site
 Liver 17 43.6
 Lung 7 17.9
Distant lymph nodes 14 35.9
 Peritoneum 7 17.9
 Multiple organs 13 33.3
CA19-9 value (U/mL)
 > 10 times of UNL 21 53.8
 ≤ 10 times of UNL 18 46.2
Patients who received 3rd line chemotherapy 12 30.8
  1. ECOG PS Eastern Cooperative Oncology Group Performance status, CA19-9 carbohydrate antigen 19-9, UNL upper normal limit